What is Rapid Genomics?
Rapid Genomics operates as a premier provider of sequencing-based genotyping and molecular-based diagnostics, serving the complex needs of the animal, plant, and microbiology industries. The company distinguishes itself through a robust integration of next-generation sequencing (NGS) and advanced computational biology. By offering bespoke assay designs and high-throughput sample processing, Rapid Genomics enables commercial enterprises to optimize production efficiency and enhance the value of their biological assets. Their proprietary bioinformatics pipeline serves as a critical bridge between raw genomic data and actionable production insights, establishing the firm as a cornerstone of modern agricultural biotechnology.
How much funding has Rapid Genomics raised?
Rapid Genomics has raised a total of $431K across 2 funding rounds:
Debt
$150K
Debt
$281K
Debt (2020): $150K with participation from PPP
Debt (2021): $281K led by PPP
Key Investors in Rapid Genomics
PPP
Public-Private Partnership
What's next for Rapid Genomics?
With the successful completion of this late-stage financing, Rapid Genomics is poised to scale its infrastructure to meet the rising demand for precision diagnostics in industrial production. The strategic roadmap likely involves the expansion of its bioinformatics capabilities and the scaling of its high-throughput laboratory facilities to accommodate larger commercial contracts. As the industry shifts toward data-driven production models, the company's focus on integrating molecular diagnostics into standard operational workflows will be essential for maintaining its competitive advantage. Future growth will likely be characterized by deeper market penetration in the microbiology sector and the continued refinement of its proprietary genotyping platforms to support global food security and production optimization initiatives.
See full Rapid Genomics company page
